Efficacy and safety of a short-time orlistat treatment in obese subjects;Efficacia e sicurezza di impiego di un trattamento a breve termine con orlistat in soggetti obesi

Annali Italiani di Medicina Interna

Volumn 20, Issue 2, 2005, Pages 90-96

  Gentile, Sandro ^a   Guarino, Giuseppina ^a   Padovano, Barbara ^a   Buonocunto, Francesco ^a   Annunziata, Stefano ^b   Armentano, Vincenzo ^b   Corigliano, Gerardo ^b   De Matteo, Antonio ^b   De Riu, Stefano ^b   Fierro, Maura ^b   Magliano, Paolo L ^b   Petraroli, Ettore ^b   Ruggiero, Alberto ^b   Pappalardo, Luigi ^b   Lucibelli, Luigi ^c   Cutolo, Michele ^d   Agrusta, Mariano ^b   Cianciullo, Marco ^b   Lambiase, Claudio ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Portici NA ^*

^c ASL NA5   (Italy)

^d Ottaviano NA

Author keywords

Exercise; Obesity; Orlistat; Therapeutic education

Indexed keywords

EID: 70049094140     PISSN: 03939340     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Obesity: preventing and managing the global epidemic. Report of a World Organization Consultation on Obesity. WHO Geneva, June 1997.
2. Astrup A. Healthy lifestyles in Europe: prevention of obesity and type II diabetes by diet and physical activity. Public Health Nutr 2001; 4: 499-515.
3. Pagano R, La Vecchia C. Overweight and obesity in Italy, 1990-1991. Int J Obes Relat Metab Disord 1994; 18: 665-9.
4. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591-602.
5. Istituto Auxologico Italiano. Il rapporto sull'obesità in Italia. Milano, 2000.
6. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000; 248: 245-54.
7. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 49-61.
8. Trento M, Passera P, Borgo E, et al. A 5-years randomized controlled study of learning, problem solving ability, and quality of life modifications in people with type 2 diabetes managed by group care. Diabetes Care 2004; 27: 670-5.
9. Fujioka K. Management of obesity as a chronic disease: non-pharmacologic, pharmacologic and surgical options. Obes Res 2002; 10 (Suppl 2): S116-S123.
10. Bray GA. Contemporary diagnosis and management of obesity. Philadelphia, PA: Newtown, 1998.
11. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276: 1907-15.
12. Racette SB, Deusinger SS, Deusinger RH. Obesity: overview of prevalence, etiology, and treatment. Phys Ther 2003; 83: 276-88.
13. Leung WY, Neil Thomas G, Chan JC, Tomlinson B. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003; 25: 58-80.
14. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 2002; 166: 1307-8.
15. Birkenfeld AL, Schroeder C, Boschmann M, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002; 106: 2459-65.
16. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21 (Suppl 3): S12-S23.
17. National Heart, Lung and Blood Institute, North American Association for the Study of Obesity. The practical guide: identification, evaluation and treatment of overweight and obesity in adults. Bethesda, MD: NIH publication n. 00-4048, 2000.
18. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167-72.
19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus prevention report of a WHO consultation. Diabet Med 1998; 15: 539-53.
20. Gentile S, per il Gruppo Educazione Terapeutica Strutturata AMD. Progetto ETS AMD. Conclusa puntualmente la seconda fase del progetto ETS. AemMeDi 2003; 6: 5-6.
21. Agrusta M, Di Berardino P, Di Pietro S, Galeone F, Gentile S, Lepri M. ETS. Educazione Terapeutica Strutturata. 3: alimentazione e stile di vita. Torino: UTET, 2002: 1-47.
22. Agrusta M, Di Berardino P, Di Pietro S, Galeone F, Gentile S, Lepri M. ETS. Educazione Terapeutica Strutturata. 4: rischio cardiovascolare. Torino: UTET, 2002: 1-38.
23. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
24. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20: 270-9.
25. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
26. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 2004; 17: 222-9.